

SIDLEY AUSTIN LLP

# SIDLEY

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C.



## CRN-I Symposium

Scientific Symposium, Nutrition Issues in Codex:  
Health Claims and Nutrient Reference Values

**11 November 2011**  
**Maurits Lugard**

# Overview

- Regulatory Food Supplement Restrictions
- Relevant Legal Framework: WTO Rules
- Application WTO Rules to:
  - RDA-based Maximum Nutrient Content Levels
  - Application of EU Health Claims Regulation



# Regulatory Food Supplement Restrictions




- Several countries restrict or are considering to restrict the sale of vitamin and mineral food supplements by establishing maximum levels of nutrient content based solely on Recommended Dietary Allowances (RDA)
- EU Health Claims Regulation as applied by the European Food Safety Authority (EFSA) and European Commission will result in prohibition of majority of health claims


# Relevance WTO Rules



- Rules of World Trade Organization can be used to address these restrictions
  - legal arguments should be part of advocacy strategy
  - WTO dispute settlement mechanism can be used by WTO Members to enforce violations of WTO rules



# WTO Membership



# Applicable WTO Rules



- WTO agreements relevant for food supplements
  - **GATT 1994**: applies to trade in goods between WTO Members
  - **SPS Agreement**: applies to sanitary and phytosanitary measures of WTO Members aimed at the protection of human, animal and plant life and health
  - **TBT Agreement**: applies to technical regulations and standards of WTO Members
- Health-related measures are addressed by both the SPS Agreement and TBT Agreement, but a measure cannot simultaneously be subject to both

**RDA-Based Maximum  
Levels of Nutrient Content  
for Vitamin and Mineral  
Food Supplements**

# Maximum Nutrient Content Levels

- Several WTO Members restrict or are considering to restrict sale of vitamin and mineral food supplements by establishing maximum levels of nutrient content



- Regulations are either in the form of
  - food regulations that prohibit production and/or sale of food supplements exceeding RDA-based limits, or
  - pharmaceutical regulations that classify all or some classes of food supplements as pharmaceutical products
- Likely justification: to protect human health

# Relevance SPS Agreement (1)

- SPS Agreement requires SPS measures to be enacted and maintained:
  - on the basis of scientific evidence and a risk assessment, or
  - on the basis of a relevant international standard
- In addition, SPS measures must be consistent with principles of non-discrimination and national treatment
- **Important:** SPS Agreement can apply irrespective of whether food supplements are regulated under food or drug regulations



## Relevance SPS Agreement (2)

- SPS Agreement urges Members to base measures on international standards such as Codex standards
- Relevant Codex standard: Codex Guidelines for Vitamins and Mineral Food Supplements
  - **explicitly warns against** setting maximum levels solely based on recommended nutrient intakes such as RDA
- SPS Agreement allows WTO Members to adopt higher level of protection than achieved by Codex standard if
  - there is a scientific justification, or
  - as a consequence of level of protection deemed appropriate by Member based on scientific risk assessment



# Violation of SPS Agreement

- Certain WTO Members' RDA-based maximum nutrient content levels appear to violate
  - Articles 2.2, 5.1 and 5.2 of SPS Agreement: they are **not based on risk assessment or maintained with sufficient scientific evidence**
  - Articles 2.3 and 5.5 of SPS Agreement: food supplement importers must comply with **standards more burdensome than those applied to producers of conventional foods** with similar qualities
  - Article 3.3 of SPS Agreement: they **exceed level of protection of relevant Codex standard without scientific justification or risk assessment**



# Relevance TBT Agreement

- TBT Agreement disciplines all technical regulations, voluntary standards and conformity assessment procedures, to extent not covered by SPS Agreement
- Objective TBT Agreement: ensure that such measures do not function as **unnecessary obstacles to international trade**
- Claims under SPS and TBT Agreement are **mutually exclusive**: if argued that national RDA-based restrictions are not covered by SPS Agreement, they are subject to TBT rules because they are “technical regulations”

# Violation of TBT Agreement (1)

- To the extent that restrictions are covered by TBT Agreement they appear to violate:



- Article 2.2 TBT Agreement: they have the effect of creating **unnecessary obstacles to international trade** by being **more trade-restrictive than necessary** to protect consumer health
  - Less trade-restrictive alternatives are available to obtain level of protection, e.g.: labeling with maximum intake information combined with higher maximum nutrient levels based on a risk assessment

## Violation of TBT Agreement (2)

- Article 2.1 TBT Agreement: to the extent that imported food supplements are “like” conventional foods of national origin, they accord **less favourable treatment to imported food supplements**
  - for example: multi-vitamin/nutritional beverages will probably be considered to be “like” conventional beverages
  - imposing RDA-based restrictions or drug-based regulations subjects food supplements to more onerous requirements than “like” conventional food products

## Violation of TBT Agreement (3)

- Article 2.4 TBT Agreement: they are **not based on the relevant Codex standard without justification**
  - RDA-based maximum levels contradict the Codex standard, and can therefore not be based on the standard
  - No justification: difficult to argue that Codex standard is ineffective or inappropriate to protect human health in this context
  - Immaterial whether regulations proceeded the Codex standard – regulations should have been reassessed

## Violation GATT 1994 (1)

- Finally, both food and drug regulations with RDA-based restrictions also:
  - appear to violate Article III:4 of GATT 1994, because, to the extent that imported food supplements are “like” certain conventional foods, they **discriminate** against imported food supplements
- the restrictions detrimentally affect the internal sale and use of food supplements by preventing the sale of imported food supplements with nutrient content exceeding RDA-based maximums



## Violation GATT 1994 (2)

- Furthermore, the violation of Article III:4 of GATT 1994
  - **Is not justified** under Article XX of GATT 1994, because the restrictions are not “necessary” to protect human health and are applied in a manner that would constitute a disguised restriction on international trade
    - While RDA-based restrictions may contribute to protecting consumers from adverse effects of excessive intakes, this is significantly outweighed by severe impact of outright prohibition on non-conforming food supplements
    - Safety-based labeling requirements, e.g., would also protect consumers similarly to RDA-based restrictions

# EU Health Claims Regulation

# Overview EU Health Claims Regulation (1)

- Adopted in December 2006 and regulates the use of nutrition and health claims made with respect to food products
- All health claims must be (1) assessed by EFSA and (2) specifically authorized by European Commission based on EFSA's analysis
- Objective is to inform consumers and protect them against misleading health claims



# Overview EU Health Claims Regulation (2)

- Three different assessment procedures:
  - Article 13(1) “general function” health claims included in list of existing health claims submitted by Member States
  - Article 13(5) health claims not covered by list of existing health claims and not subject to Article 14
  - Article 14 health claims related to reduction of disease risk and children’s development and health
- List of permitted Article 13(1) claims was supposed to be adopted by January 31, 2010 – now expected by end of 2010 / early 2011



# Overview EU Health Claims Regulation (3)

- Restrictive application by EFSA resulted in negative opinion on more than 85 % of claims relating to food supplements not containing vitamins or minerals
- Main issues:
  - EFSA failed to weigh the totality of evidence
  - applied drug-like standards to claims for food products
  - failed to apply different standards to different claims
- If European Commission follows EFSA opinions, all these claims can no longer be used once list of permitted claims is published



# Relevance TBT Agreement

- TBT Agreement applies to EU Health Claims Regulation because it is a “technical regulation”
  - it sets forth product characteristics in the form of labeling requirements;
  - compliance with the labeling requirements is mandatory; and
  - the requirements apply to an identifiable group of products: foods
- And provides for “conformity assessment procedure”
  - before health claims can be used they must be assessed by EFSA and authorized by EU legislator

# Violation TBT Agreement (1)

- Restrictive application of EU Health Claims Regulation by EFSA and European Commission appears to violate Article 2.2 TBT Agreement:

- it is **more trade restrictive than necessary** to achieve the objective of preventing misleading health claims on food products and creates an **unnecessary obstacle** to international trade



- trade restrictive impact severe if European Commission acts in accordance with EFSA opinions
- more reasonable EFSA assessment standard would not lead to significant risks for consumers and would still prohibit misleading and deceptive claims

## Violation TBT Agreement (2)

- In addition, the procedures to assess conformity of health claims with legal requirements as applied by EFSA appear to violate Article 5.1.2 TBT Agreement:
  - they are **applied more strictly than necessary** to prevent the use of misleading health claims in the EU
    - EFSA did not take into account totality of available scientific evidence and does not weigh all the evidence
    - EFSA applied drug-like standards to claims for food products and rejected many studies as “not pertinent”
    - EFSA failed to apply different standards to different claims and subjected all claims to highest standards
  - approach **goes beyond legal standards** and prevents products with health claims supported by evidence from being marketed in the EU



**More detailed legal memoranda have been  
published on CRN website**

**Questions/Comments**



**Maurits Lugard**

Partner

**Head EU Life Sciences Regulatory Practice**

Sidley Austin LLP

Rue Montoyer 51

1000 Brussels, Belgium

Tel: +322-504-6400 (office)

E-mail: [mlugard@sidley.com](mailto:mlugard@sidley.com)

# World Offices

## BEIJING

Suite 608, Tower C2  
Oriental Plaza  
No. 1 East Chang An Avenue  
Dong Cheng District  
Beijing 100738  
China  
T: 86.10.6505.5359  
F: 86.10.6505.5360

## BRUSSELS

Square de Meeûs, 35  
B-1000 Brussels  
Belgium  
T: 32.2.504.6400  
F: 32.2.504.6401

## CHICAGO

One South Dearborn  
Chicago, Illinois 60603  
T: 312.853.7000  
F: 312.853.7036

## DALLAS

717 North Harwood  
Suite 3400  
Dallas, Texas 75201  
T: 214.981.3300  
F: 214.981.3400

## FRANKFURT

Taunusanlage 1  
60329  
Frankfurt am Main  
Germany  
T: 49.69.22.22.1.4000  
F: 49.69.22.22.1.4001

## GENEVA

Rue de Lausanne 139  
Sixth Floor  
1202 Geneva  
Switzerland  
T: 41.22.308.00.00  
F: 41.22.308.00.01

## HONG KONG

Level 39  
Two Int'l Finance Centre  
8 Finance Street  
Central, Hong Kong  
T: 852.2509.7888  
F: 852.2509.3110

## LONDON

Woolgate Exchange  
25 Basinghall Street  
London, EC2V 5HA  
United Kingdom  
T: 44.20.7360.3600  
F: 44.20.7626.7937

## LOS ANGELES

555 West Fifth Street  
Los Angeles, California 90013  
T: 213.896.6000  
F: 213.896.6600

## NEW YORK

787 Seventh Avenue  
New York, New York 10019  
T: 212.839.5300  
F: 212.839.5599

## PALO ALTO

1001 Page Mill Road  
Building 1  
Palo Alto, California 94304  
T: 650.565.7000  
F: 650.565.7100

## SAN FRANCISCO

555 California Street  
San Francisco, California 94104  
T: 415.772.1200  
F: 415.772.7400

## SHANGHAI

Suite 1901  
Shui On Plaza  
333 Middle Huai Hai Road  
Shanghai 200021  
China  
T: 86.21.2322.9322  
F: 86.21.5306.8966

## SINGAPORE

6 Battery Road  
Suite 40-01  
Singapore 049909  
T: 65.6230.3900  
F: 65.6230.3939

## SYDNEY

Level 10, 7 Macquarie Place  
Sydney NSW 2000  
Australia  
T: 61.2.8214.2200  
F: 61.2.8214.2211

## TOKYO

Sidley Austin Nishikawa  
Foreign Law Joint Enterprise  
  
Marunouchi Building 23F  
4-1, Marunouchi 2-chome  
Chiyoda-Ku, Tokyo 100-6323  
Japan  
T: 81.3.3218.5900  
F: 81.3.3218.5922

## WASHINGTON, D.C.

1501 K Street N.W.  
Washington, D.C. 20005  
T: 202.736.8000  
F: 202.736.8711

Sidley Austin LLP, a Delaware limited liability partnership which operates at the firm's offices other than Chicago, London, Hong Kong, Singapore and Sydney, is affiliated with other partnerships, including Sidley Austin LLP, an Illinois limited liability partnership (Chicago); Sidley Austin LLP, a separate Delaware limited liability partnership (London); Sidley Austin LLP, a separate Delaware limited liability partnership (Singapore); Sidley Austin, a New York general partnership (Hong Kong); Sidley Austin, a Delaware general partnership of registered foreign lawyers restricted to practicing foreign law (Sydney); and Sidley Austin Nishikawa Foreign Law Joint Enterprise (Tokyo). The affiliated partnerships are referred to herein collectively as Sidley Austin, Sidley, or the firm.